SUPREME-DM - About

        Primary Research Aims:

      • Develop a comprehensive, longitudinal diabetes clinical registry and data infrastructure
        • Identify and monitor trends in type 1 and type 2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and pre-diabetes
        • incidence/prevalence
        • treatment patterns
        • outcomes
        • Implement medication adherence intervention
        • Brief counseling for diabetic patients with newly prescribed medications for glycemic control, dislipidemia, or hypertension
        • Investigate weight loss counseling for women with recent GDM
        • Abnormal postpartum glucose test
        • Understand relationship between weight loss and communication, counseling, and referral strategies


      Study Design/Methods:


        • DataLink Core
        • Develop a comprehensive, longitudinal diabetes clinical registry and data infrastructure
        • Identify and monitor trends in type 1 and type 2 DM, GDM, and pre-diabetes
        • incidence/prevalence
        • treatment patterns
        • outcomes
        • Prevention Core
        • Conduct an observational CER cohort study at three centers
        • Involve pregnant women who developed GDM during a recent pregnancy
        • Examine the effectiveness of follow-up approaches: postpartum glucose testing, communication, couseling, and referral strategies
        • Natural Language Processing (NLP) Core
        • Develop two software applications
        • Assess use of behavioral counseling for medication adherence and weight loss in women with GDM
        • Patient-Centered and Self-Management Core
        • Work closely with the DataLink, Prevention, and Treatment Core studies to measure medication adherence and conceptualize/measure patient-centered, patient-reported variable
        • Treatment Core
        • Employ a cluster-randomized compartative effectiveness research (CER) intervention at four healthcare systems
        • Identify patients with DM, uncontrolled cardiovascular disease (CVD) risk factors (A1c, LDL-c, or SBP) with newly prescribed medications to treat those conditions
        • Provide tools/strategies to address early non-adherence